New Imaging Breakthrough Quickly Predicts Cancer Drug Response in Patient Tumor Models

Technology Innovation /

Researchers have developed a new imaging method that rapidly predicts how cancer drugs will work in patient-derived tumor models. Patient-derived cancer organoids (PDCOs) are 3D models grown from a patient’s tumor, providing a realistic way to study treatment response, but current tests often miss resistant cells and early changes. The technique, Wide-Field Optical Redox Imaging […]

New Imaging Breakthrough Quickly Predicts Cancer Drug Response in Patient Tumor Models Read More »

New MST-AI Method Boosts Skin Cancer Detection Accuracy for Darker Skin Tones

Diagnostics /

Researchers have introduced a new AI method called MST-AI that aims to make skin cancer detection more accurate and fair for people with darker skin tones. Many current AI tools used to detect melanoma work well on lighter skin but often fail on darker skin because the training images they rely on are not diverse

New MST-AI Method Boosts Skin Cancer Detection Accuracy for Darker Skin Tones Read More »

MUC18-Targeted ADC AMT-253 Shows Strong Early Efficacy in Melanoma and Gynecologic Cancers

Targeted Therapy /

AMT-253, a MUC18-targeted antibody-drug conjugate, has shown encouraging results in two phase 1 melanoma studies. Among 56 evaluable melanoma patients, the overall response rate was 28.6%, with 15 confirmed partial responses, and the disease control rate reached 73.2%. Responses varied by melanoma subtype, with acral and unknown primary melanoma showing particularly strong disease control. Patients

MUC18-Targeted ADC AMT-253 Shows Strong Early Efficacy in Melanoma and Gynecologic Cancers Read More »

New Metal-Based Complexes Poised to Replace Cisplatin in Next-Generation Cancer Therapy

Treatment /

Organometallic complexes—cancer-fighting compounds built around metal-carbon bonds—are emerging as a more selective alternative to traditional platinum drugs like cisplatin. While platinum treatments remain effective, they often damage healthy cells and quickly lead to resistance. New metal-based designs aim to target cancer more precisely and avoid these limitations. Cyclometalated complexes are especially promising because their chemistry

New Metal-Based Complexes Poised to Replace Cisplatin in Next-Generation Cancer Therapy Read More »

New Insights Into ROS and Autophagy Reveal Why Thyroid Cancer Resistance Is Rising

Research Advances /

common cancer by 2030. While survival rates are generally high, drug resistance and reduced sensitivity to radioactive iodine (RAI) remain major challenges. New research highlights the role of reactive oxygen species (ROS) and autophagy in driving resistance and shaping potential therapies. Most cases are Differentiated Thyroid Cancer (DTC), especially Papillary Thyroid Carcinoma (PTC), which accounts for about 85% of

New Insights Into ROS and Autophagy Reveal Why Thyroid Cancer Resistance Is Rising Read More »

NaPi2b-Targeted ADC TUB-040 Shows Promising Results in Platinum-Resistant Ovarian Cancer

Treatment /

NaPi2b, a sodium-dependent phosphate transporter, is emerging as a promising target for platinum-resistant ovarian cancer, a setting with few effective treatments. Highly expressed in high-grade serous ovarian, fallopian tube, and peritoneal cancers—but low in normal tissue—NaPi2b is ideal for selective delivery via antibody-drug conjugates (ADCs). Earlier NaPi2b-targeted ADCs, like lifastuzumab vedotin and upifitamab rilsodotin, showed

NaPi2b-Targeted ADC TUB-040 Shows Promising Results in Platinum-Resistant Ovarian Cancer Read More »

FDA Approves Ziftomenib, a New Targeted Therapy for NPM1-Mutated Relapsed AML

Drug Approvals /

The FDA has approved ziftomenib (Komzifti) for adults with relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations and lacking other effective treatments. This provides a new option for a challenging AML subgroup. Approval was based on the phase 1/2 KOMET-001 trial, which showed a 21.4% complete remission (CR/CRh) rate, with responses lasting a median of five

FDA Approves Ziftomenib, a New Targeted Therapy for NPM1-Mutated Relapsed AML Read More »

Anito-cel CAR T Therapy Shows 97% Response Rate in Refractory Multiple Myeloma

Immunotherapy /

Anito-cel is a novel CAR T-cell therapy for multiple myeloma that reprograms a patient’s T-cells to target BCMA (B-cell maturation antigen). It uses a fully humanized D-domain binder for enhanced uptake, faster release from targets, stronger CAR expression, and lower risk of immune-related complications. In the phase 2 iMMagine-1 trial with 117 heavily pretreated patients, anito-cel achieved

Anito-cel CAR T Therapy Shows 97% Response Rate in Refractory Multiple Myeloma Read More »

Astatine-211 Production for Next-Generation Targeted Cancer Therapy

Targeted Therapy /

Scientists have developed a new way to produce, isolate, and ship astatine-211 (At-211), a rare and unstable radioactive isotope with strong potential for targeted cancer therapy. Known as a “Goldilocks isotope,” At-211 is considered ideal for cancer treatment because it delivers powerful, localized bursts of energy that can kill cancer cells without harming nearby healthy

Astatine-211 Production for Next-Generation Targeted Cancer Therapy Read More »

TAR-200 Implant Shows Remarkable Success in Treating Resistant Bladder Cancer

Technology Innovation /

TAR-200, a novel bladder implant delivering gemcitabine, shows striking results for high-risk, non-muscle-invasive bladder cancer that failed prior treatments. The pretzel-shaped device is inserted via catheter and slowly releases chemotherapy over three weeks, allowing prolonged contact with tumors compared with standard liquid therapy. In the phase 2 SunRISe-1 trial, 82% of 85 patients achieved complete

TAR-200 Implant Shows Remarkable Success in Treating Resistant Bladder Cancer Read More »